行情

CORV

CORV

Correvio Pharma Corp
NASDAQ

实时行情|Nasdaq Last Sale

0.2800
-0.0005
-0.18%
交易中 12:13 02/20 EST
开盘
0.2712
昨收
0.2805
最高
0.2940
最低
0.2710
成交量
112.74万
成交额
--
52周最高
4.440
52周最低
0.2100
市值
1,414.60万
市盈率(TTM)
-0.3110
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CORV 新闻

  • 飞利浦据称选择高盛和摩根大通负责家电业务的出售
  • 新浪财经.3小时前
  • 摩根士丹利以130亿美元全股票交易收购E*Trade
  • 新浪财经.3小时前
  • 黄金再刷7年新高!花旗认为可能还有25%的上涨空间
  • 新浪财经综合.3小时前
  • 苹果考虑允许将第三方浏览器和邮件设为默认
  • 新浪科技.4小时前

更多

所属板块

制药
-0.96%
制药与医学研究
-0.99%

热门股票

名称
价格
涨跌幅

CORV 简况

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
展开

Webull提供Correvio Pharma Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。